Catarina Silva of Immuno-Oncology News reports on innovative five-year partnership involving GE Healthcare and Vanderbilt University Medical Center (VUMC). The two aim to develop new diagnostic tools to predict how an immunotherapy will work—with a focus on effectiveness and safety—prior to be given to a specific patient. The goal is to allow doctors to better treat their patients with the goal of precluding potentially damaging, ineffective and expensive treatments.
“Immunotherapy offers tremendous promise, but given the current unpredictability of some patients’ reactions to treatments, it is also associated with increased morbidity and cost. This partnership provides the opportunity to leverage strengths of both of our organizations to further personalize cancer care by creating new tools that allow clinicians to more accurately predict how patients will respond to a specific therapy,” Jeff Balser, MD, PhD, president and CEO of VUMC and dean of the Vanderbilt University School of Medicine.
The partnership will also focus on the development of a new positron-emission tomography (PET) imaging tracers. PET scanning can measure blood volume, oxygen usage, sugar metabolism and drug activity. The two will also team up to introduce new stem cell transplant processes.